Abstract
POST-COITAL emergency contraception hasn’t had a “new look” for some years. Indeed, research demonstrating that increased availability of post-coital contraception seems not to have reduced abortion rates has given it a distinctly passé feel. When discussion in expert groups began to shift the focus away from increasing its use to its role in “bridging” women to other methods, post-coital contraception seemed to have passed its prime.
However, news of the launch of ellaOne® by HRA Pharma, a young, private European pharmaceutical company, was welcomed enthusiastically by post-coital contraception supporters at the annual meeting of the International Consortium for Emergency Contraception in New York in September 2009.
